Incyclix Bio

About Incyclix Bio

Incyclix Bio, LLC operates as a clinical-stage biopharmaceutical company focused on developing precision treatments for cancer by targeting the cell cycle. The company was founded in 2020, initially as Arc Therapeutics, by a team of scientists with extensive experience in cyclin-dependent kinase (CDK) inhibitor research spun out of G1 Therapeutics. The founders include Patrick Roberts, Jay Strum, John Bisi, and Fredric N. Eshelman, who collectively bring a history of successful drug development. Their journey began over a decade ago at G1 Therapeutics, where their work on the CDK4/6 inhibitor Cosela (trilaciclib) also highlighted CDK2 as a promising target for cancers that develop resistance. This insight led them to license the cell cycle program from G1 and establish Incyclix Bio to concentrate on this area of unmet medical need.

The company's core business is the discovery and development of small molecule inhibitors of CDKs to treat advanced and resistant cancers. Its business model is centered on advancing its pipeline through clinical trials, a capital-intensive process funded by venture capital. Incyclix Bio generates value by achieving clinical milestones, such as FDA clearances and positive trial data, with the ultimate goal of bringing a product to market, likely through a strategic partnership or acquisition by a larger pharmaceutical company. To date, the company has successfully raised significant capital, including a $30 million Series B round in March 2022 and an $11.25 million extension in August 2025, from investors such as Boxer Capital, RA Capital Management, Eshelman Ventures, and Eli Lilly and Company.

Incyclix Bio's lead product candidate is INX-315, a potent and selective oral inhibitor of CDK2. This compound is being developed to address the significant challenge of treatment resistance in various cancers, particularly in tumors where aberrant cell proliferation is driven by CDK2. The primary target patient populations include those with ER+/HER2- breast cancer that has become resistant to existing CDK4/6 inhibitor therapies and patients with other solid tumors characterized by CCNE1 amplification, such as certain ovarian cancers. INX-315 is currently being evaluated in a Phase 1/2 clinical trial (NCT05735080) to assess its safety, tolerability, and preliminary anti-tumor activity. The U.S. FDA has recognized the potential of this drug by granting it Fast Track designation for treating CCNE1-amplified platinum-resistant/refractory ovarian cancer, highlighting its promise in an area with high unmet need.